Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy

INTRODUCTION: Intravenous (IV) voriconazole is not recommended in patients with creatinine clearance <50 ml/min to avoid potentially toxic accumulation of sulfobutylether-β-cyclodextrin (SBECD). The purpose of this study was to evaluate the pharmacokinetics of SBECD, voriconazole, and voriconazol...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Crit Care
Autors principals: Kiser, Tyree H, Fish, Douglas N, Aquilante, Christina L, Rower, Joseph E, Wempe, Michael F, MacLaren, Robert, Teitelbaum, Isaac
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4338618/
https://ncbi.nlm.nih.gov/pubmed/25645660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13054-015-0753-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars